GlassScriptPhysician profile
James M Randall
NPI 1144407115
$1,526.05
in general payments reported to CMS, 2019-2025
20 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $207 · 2021: $32.18 · 2022: $125 · 2023: $201 · 2024: $399 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $739.39 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $607.27 | 2019-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $220.12 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Aveo Pharmaceuticals, INC. | $184.49 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $118.01 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $62.60 | 2019-2024 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $59.25 | 2021-2024 | |
| Tempus Ai, INC | $54.49 | 2024-2025 | Xt Cdx |
| Sumitomo Pharma America, INC. | $53.82 | 2025 | Orgovyx |
| Eisai INC. | $41.41 | 2023-2024 | |
| 180 Medical, INC. | $28.65 | 2020 | |
| Janssen Biotech, INC. | $27.93 | 2025 | Erleada |
| Astellas Pharma US INC | $23.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.41 | 2022 | |
| Blue Earth Diagnostics | $21.76 | 2024 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.